Helius Medical Technologies Inc
NASDAQ:HSDT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Helius Medical Technologies Inc
Retained Earnings
Helius Medical Technologies Inc
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Helius Medical Technologies Inc
NASDAQ:HSDT
|
Retained Earnings
-$212.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-25%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Retained Earnings
$5.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Retained Earnings
$14.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
16%
|
|
|
Stryker Corp
NYSE:SYK
|
Retained Earnings
$20.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Retained Earnings
$49.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Retained Earnings
$7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
17%
|
CAGR 10-Years
23%
|
|
Helius Medical Technologies Inc
Glance View
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania. The company went IPO on 2014-06-27. The firm focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The firm's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The firm's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.
See Also
What is Helius Medical Technologies Inc's Retained Earnings?
Retained Earnings
-212.6m
USD
Based on the financial report for Dec 31, 2025, Helius Medical Technologies Inc's Retained Earnings amounts to -212.6m USD.
What is Helius Medical Technologies Inc's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-25%
Over the last year, the Retained Earnings growth was -24%. The average annual Retained Earnings growth rates for Helius Medical Technologies Inc have been -12% over the past three years , -12% over the past five years , and -25% over the past ten years .
